Clinical trial
A First In Human Study Of PF-00184562 In Healthy Volunteers
NCT00150215 · Pfizer, Industry · Completed
Key facts
| NCT number | NCT00150215 |
|---|---|
| Title | A First In Human Study Of PF-00184562 In Healthy Volunteers |
| Official title | An Oral, Rising Single-Dose Tolerance, Pharmacokinetic, and Pharmacodynamic Study of Pf-00184562 Capsules In Healthy Volunteers |
| Lead sponsor | Pfizer, Industry |
| Collaborators | PPD Development, LP Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Schizophrenia |
| Intervention type | Drug |
| Interventions | PF-00184562, Olanzapine |
| Enrollment | 18 |
| Start date | Jul 1, 2005 |
| Completion | Oct 1, 2005 |
| First posted | Sep 8, 2005 |
| Last update posted | Jul 25, 2006 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: